• Home Adeona receives $488.

Adeona receives $488.

If effective, Adeona expects to make its Zinthionein item commercially obtainable as a prescription medical meals for patients suffering from Alzheimer’s disease and moderate cognitive impairment. More info on the clinical research is offered by Related StoriesMultiple sclerosis relapse management: an interview with Gina RemingtonRegular exercise benefits children with multiple sclerosisStudy displays guarantee for developing targeted remedies for multiple sclerosisIn August 2010, Adeona announced that nearly two-thirds of the patients have been enrolled in the clinical trial analyzing Trimesta in women experiencing relapsing-remitting multiple sclerosis.Related StoriesDeaths from avoidable risk factors: an interview with Dr Ali Mokdad, IHMEDiabetic retinopathy therapy improvements: an interview with Richard Kirk, CEO of PolyphotonixStudy backs more intense blood circulation pressure treatment, says ACC President Kim Allan WilliamsThe upsurge in prevalence of high blood pressure is mostly related to the number of people with the condition in developing areas. The prevalence of high blood pressure is set to increase by 24 percent in developed countries and by 80 percent in developing countries.